Pacific Biosciences of California Stock: This news comes at just the right time! ()

Pacific Biosciences Of California, a company from the “Life Sciences Tools and Services” market, is currently (as of 02:00 a.m.) listed at USD 5.72 in the red (-1.89 percent), the company’s home stock exchange is NASDAQ GS.

In an in-house analysis, we evaluated Pacific Biosciences Of California according to the 7 most important factors based on the current data. This results in an evaluation as “Buy”, “Hold” or “Sell”. These 7 different individual factors then lead to a consolidated overall assessment of the prospects for the stock.

1. Analyst rating: In the past 12 months, analysts have given Pacific Biosciences Of California 2 buy ratings, 0 hold ratings and 0 sell ratings. In the long term, the stock will therefore receive a “buy” rating from the institutional side. There are no analyst updates for Pacific Biosciences Of California from the last month. Finally, the analysts are also concerned with the current price of USD 5.83. On this basis, they expect a development of 671.87 percent and generate a middle target price of USD 45. We regard this development as a “buy” view. In this respect, the overall rating by institutional analysts is “Buy”.

2. Investors: A look at the discussion in social media shows the following picture: In the last few days, market participants were generally positive towards Pacific Biosciences Of California. There were a total of 12 positive and two negative days. The latest news from the past day or two about the company is also mostly positive. Based on our sentiment analysis, Pacific Biosciences Of California is therefore given a Buy rating. Overall, Pacific Biosciences Of California receives a “buy” rating from the editors for investor sentiment.

Read also  "First step for living photovoltaics", the Swiss study on bacteria that absorb carbon nanotubes

3. Fundamental: At a price-to-earnings (P/E) ratio of 362.56, Pacific Biosciences Of California stock is 431 percent higher than its peers in the life sciences tools and services industry based on today’s prices ( 68.3) are evaluated. This indicator, in turn, signals an undervaluation. From the perspective of fundamental analysis, this results in the classification “Sell”.

Buy, hold or sell – your Pacific Biosciences of California analysis dated 22.09. gives the answer:

How will Pacific Biosciences of California develop now? Is an entry worthwhile or should investors rather sell? Find out the answers to these questions and why you need to act now in the latest Pacific Biosciences of California analysis.

<!–table b {color:#ffffff !important;}